Short answer
Johnson & Johnson (JNJ) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). $5.5B commitment to resolve ovarian talc litigation with leading plaintiff firms.
Johnson & Johnson 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- $5.5B commitment to resolve ovarian talc litigation with leading plaintiff firms
- Settlement requires participation from at least 95% of remaining claims
- Initial payment capped at $3B in 2027, with no additional payments before 2028
- Potential litigation overhang reduction, contingent on achieving required claimant participation
Item EX-99.1 · Exhibit EX-99.1
- Proposed $5.5B resolution for remaining ovarian talc claims, subject to participation representing at least 95% of claims
- First payment capped at $3B in 2027, with no additional payments due before 2028
- Resolution addresses approximately 76,000 remaining ovarian talc claims and removes ongoing litigation expense
- Agreement follows July 22, 2026 MDL ruling challenging plaintiffs’ ability to prove specific causation
- Johnson & Johnson retains talc liabilities and indemnification obligations for Kenvue claims
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Johnson & Johnson 8-K filings
Get the next JNJ 8-K as it lands
Follow JNJ for push alerts, or ask the research agent what this filing means.